ONC vs. RDY: BeOne Medicines vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

BeOne Medicines (ONC) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while RDY is classified in Pharmaceuticals.

Both BeOne Medicines (ONC) and Dr. Reddy's Laboratories (RDY) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BeOne Medicines (ONC) at 18.40% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both BeOne Medicines (ONC) at 13.86% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both BeOne Medicines (ONC) at 40.23% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports EPS growth of -24.14%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Dr. Reddy's Laboratories (RDY) at 1.93 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RDY.

Both BeOne Medicines (ONC) at 0.35 and Dr. Reddy's Laboratories (RDY) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

Dr. Reddy's Laboratories (RDY) at 41.42 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Both look rich against book: BeOne Medicines (ONC) at 7.98 sits in the upper P/B ratio quartile, and Dr. Reddy's Laboratories (RDY) at 18.16 prices even higher, above its industry range.

Valuation Metrics